Guidelines for mono, double and triple antithrombotic therapy

Renate C. A. E. van Uden, Ilse Houtenbos, Anita Griffioen-Keijzer, Diego A. M. Odekerken, Patricia M. L. A. van den Bemt, Matthijs L. Becker*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

8 Downloads (Pure)

Abstract

Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.

Original languageEnglish
Pages (from-to)730-737
Number of pages8
JournalPostgraduate medical journal
Volume97
DOIs
Publication statusPublished - Nov-2021

Keywords

  • anticoagulation
  • protocols & guidelines
  • DUAL ANTIPLATELET THERAPY
  • CORONARY-ARTERY-DISEASE
  • ESC FOCUSED UPDATE
  • ATRIAL-FIBRILLATION
  • EUROPEAN-SOCIETY
  • ESC/EACTS GUIDELINES
  • CARDIOLOGY ESC
  • TASK-FORCE
  • RISK
  • MANAGEMENT

Cite this